FDA Alerts
FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
The Food and Drug Administration approved azacitidine (Vidaza, Celgene Corp.) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
Read moreFDA Approves Axicabtagene Ciloleucel for Second-line Treatment of Large B-cell Lymphoma
The Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoi...
Read moreEmergency Use Authorization: Drugs and Non-Vaccine Biological Products
The HHS Secretary declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic.
Read moreFDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals
The Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.
Read moreFDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
The Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome i...
Read moreFDA Approves Treatment for Adults with Rare Type of Anemia
FDA has approved Enjaymo (sutimlimab-jome) infusion to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD).
Read moreFDA Approves Drug to Treat Sickle Cell Disease in Patients Aged 4 up to 11 Years
The FDA has granted accelerated approval for Oxbryta (voxelotor) tablets to treat sickle cell disease in pediatric patients aged four up to 11 years.
Read moreFDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease
The Food and Drug Administration approved abatacept (Orencia, Bristol-Myers Squibb Company) for the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and pediat...
Read moreFDA Approves Rituximab plus Chemotherapy for Pediatric Cancer Indications
The Food and Drug Administration approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lympho...
Read moreFDA Approves Darzalex Faspro, Kyprolis, and Dexamethasone for Multiple Myeloma
The Food and Drug Administration approved daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have re...
Read more- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10